APA citáció

Géczi Lajos, Bodoky György, Rokszin György, Bajcsayné Fábián Ibolya, & Torday László. (2020). Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma.

Chicago Style (17th ed.) Citation

Géczi Lajos, Bodoky György, Rokszin György, Bajcsayné Fábián Ibolya, and Torday László. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. 2020.

MLA idézés

Géczi Lajos, et al. Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. 2020.